Alyssa Dantonio

An oral SARS-CoV-2 M ^pro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.8K citations · Full text

Viral Diagnostics, Worldwide Outbreak, Immunology +16

Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans

Heather Eng, Alyssa Dantonio, Eugene P. Kadar et al. · Drug Metabolism and Disposition · 2022 · 111 citations · Full text

A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19

Charlotte Allerton, Joel T. Arcari, Lisa Aschenbrenner et al. · Journal of Medicinal Chemistry · 2024 · 59 citations · Full text

Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity

Brahim Achour, Alyssa Dantonio, Mark Niosi et al. · Drug Metabolism and Disposition · 2017 · 40 citations · Full text

Data Generated by Quantitative Liquid Chromatography-Mass Spectrometry Proteomics Are Only the Start and Not the Endpoint: Optimization of Quantitative Concatemer-Based Measurement of Hepatic Uridine-5′-Diphosphate–Glucuronosyltransferase Enzymes with Reference to Catalytic Activity

Brahim Achour, Alyssa Dantonio, Mark Niosi et al. · Drug Metabolism and Disposition · 2018 · 23 citations · Full text